Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1995 1
1996 1
1997 2
1998 1
1999 2
2000 3
2001 2
2002 4
2003 2
2004 6
2005 4
2006 4
2007 4
2008 3
2009 4
2010 4
2011 4
2012 6
2013 5
2014 6
2015 10
2016 6
2017 3
2018 5
2019 8
2020 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30407097

91 results

Results by year

Filters applied: . Clear all
Page 1
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S. Feugier P, et al. Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545348 Free PMC article. No abstract available.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group. García-Marco JA, et al. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. Haematologica. 2019. PMID: 30890600 Free PMC article.
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators. Österborg A, et al. Haematologica. 2015 Aug;100(8):e311-4. doi: 10.3324/haematol.2014.121459. Epub 2015 Mar 13. Haematologica. 2015. PMID: 25769539 Free PMC article. No abstract available.
91 results